4 completed, 4 not yet recruiting, 2 active not recruiting, 2 recruiting. 8 Phase 2, 2 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Not yet recruiting 3, Completed 2, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Not applicable | 2 | Recruiting 2 |
| Phase 1 | 1 | Unknown 1 |
Follow Tertiary Lymphoid Structures: new trials by email Literature Review of Tertiary Lymphoid Structures trials Research Report on Tertiary Lymphoid Structures
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy - Metastatic Non-Clear Cell Renal Cell Carcinoma, Metastatic Renal Medullary Carcinomas | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-09-20 | 2026-09-14 |
| TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy - Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-08-20 | 2026-08-20 |
| Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC) | Not yet recruiting | Assiut University | 100 | 2026-05-01 | 2026-04-13 | |
| MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors. MEDI5752 - Advanced Solid Tumor | Phase 2 | Not yet recruiting | Institut Bergonié | 102 | 2025-09-01 | 2025-08-13 |
| Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma Nasopharyngeal Cancinoma (NPC) | Active not recruiting | Jiangxi Provincial Cancer Hospital | 260 | 2025-01-01 | 2025-01-13 | |
| Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma Immunotherapy combined with targeted therapy, Standard treatment plan - Hepatocellular Carcinoma, Immunotherapy | Not applicable | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2024-09-01 | 2025-02-10 |
| Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures Ezabenlimab + BI907828 - Adult Soft Tissue Sarcoma, Non Small Cell Lung Cancer | Phase 2 | Withdrawn | Institut Bergonié | 2024-06-14 | 2025-09-02 | |
| Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD) Additional blood sample, cGVHD target tissue biopsy - Chronic Graft Versus Host Disease | Not applicable | Recruiting | University Hospital, Bordeaux | 70 | 2024-05-21 | 2026-07-16 |
| Elements of Adaptive Immunity in Epithelial Ovarian Cancer Assessment of elements of adaptive immunity in tumor biopsies - Epithelial High Grade Serous Ovarian Cancer | Completed | Hellenic Cooperative Oncology Group | 687 | 2023-04-01 | 2026-07-27 | |
| Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma Bintrafusp alfa, Doxorubicin - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Phase 2 | Active not recruiting | Institut Bergonié | 80 | 2022-03-01 | 2026-07-24 |
| Combining Epigenetic And Immune Therapy to Beat Cancer. Durvalumab, Tazemetostat - Advanced Solid Tumor, Advanced Colorectal Carcinoma | Phase 2 | Completed | Institut Bergonié | 164 | 2021-07-23 | 2026-03-06 |
| Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study Association of Nivolumab + Relatlimab, Nivolumab - Soft Tissue Sarcoma Adult, Advanced Cancer | Phase 2 | Completed | Institut Bergonié | 68 | 2020-02-27 | 2026-04-21 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST | Phase 1 / Phase 2 | Unknown | Institut Bergonié | 747 | 2018-05-04 | 2023-03-03 |
| Machine Learning Model Guided by TLS Predicts Survival and Immune Features in Gastric Cancer TLS-Informed Machine Learning Prognostic Model - Locally Advanced Gastric Cancer, Tumor Immune Microenvironment | Completed | Qun Zhao | 1200 | 2012-01-01 | 2025-05-20 |
Sarcoma (5) · Carcinoma, Renal Cell (3) · Neoplasm Metastasis (3) · Biliary Tract Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (2) · Colorectal Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Bronchiolitis Obliterans Syndrome (1) · Clear-cell metastatic renal cell carcinoma (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Mesothelioma, Malignant (1) · Neoplasms (1)
Pathological Conditions, Anatomical (14) · Pathological Conditions, Signs and Symptoms (14) · Neoplasms by Histologic Type (9) · Neoplasms (8) · Neoplasms by Site (7) · Carcinoma (5) · Neoplasms, Connective and Soft Tissue (5) · Neoplasms, Glandular and Epithelial (5) · Adenocarcinoma (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Urogenital Diseases (4)
Axitinib (2) · toripalimab (2) · Clinical Trials, Phase II as Topic (1) · Doxorubicin (1) · Nivolumab (1) · bintrafusp alfa protein, human (1) · brigimadlin (1) · durvalumab (1) · regorafenib (1) · relatlimab (1) · tazemetostat (1)
Institut Bergonié (6) · Fudan University (2) · Assiut University (1) · Hellenic Cooperative Oncology Group (1) · Jiangxi Provincial Cancer Hospital (1) · Qun Zhao (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · University Hospital, Bordeaux (1)
France (7) · China (2) · Greece (1)
PMID 34965951, PMID 34998048, PMID 40204996, PMID 40579407
2019 (2), 2023 (2), 2016 (1)